Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation

British Journal of Pharmacology

Volumn 159, Issue 8, 2010, Pages 1581-1583

  Lendeckel, Uwe ^a   Dobrev, Dobromir ^b   Goette, Andreas ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Aldosterone; Apoptosis; Atrial remodelling; Fibrillation; Fibrosis; Rapid pacing; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; OMEGA 3 FATTY ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; STEROID;

BLOOD CLOTTING; CLINICAL TRIAL; ENZYME ACTIVATION; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ALDOSTERONE ANTAGONISTS; ATRIAL FIBRILLATION; HUMANS; RECEPTORS, ALDOSTERONE; SPIRONOLACTONE;

EID: 77950245742     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00675.x     Document Type: Note

References (11)

1. Goette A, Arndt M, Röcken C, Spiess A, Staack T, Geller JC et al. (2000a). Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101 : 2678 2681.
2. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C et al. (2000b). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35 : 1669 1677.
3. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU (2001). Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 88 : 906 909.
4. Gómez AM, Rueda A, Sainte-Marie Y, Pereira L, Zissimopoulos S, Zhu X et al. (2009). Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 119 : 2179 2187.
5. Lemarié CA, Simeone SMC, Nikonova A, Ebrahimian T, Deschênes M-E, Coffman TM et al. (2009). Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res 105 : 852 859.
6. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E et al. (2005). Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26 : 2193 2199.
7. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T et al. (2007). Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 76 : 506 516.
8. Pei DA, Li L, Xu ZY, Zou LJ, Zhang BR, Huang SD et al. (2007). Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases. Zhonghua Yi Xue Za Zhi 87 : 816 819.
9. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS (2006). Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17 : 534 541.
10. Sun Y, Ramires FJ, Weber KT (1997). Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 35 : 138 147.
11. Zhao J, Li J, Li Y, Shan H, Gong Y, Yang B (2010). Effects of spironolactone on atrial structural remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 159 : 1584 1594.